- Home
- LRMR vs CGEN Comparison
LRMR vs CGEN Comparison
Compare LRMR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- CGEN
- Stock Information
- Founded
- LRMR N/A
- CGEN 1993
- Country
- LRMR United States
- CGEN Israel
- Employees
- LRMR N/A
- CGEN N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRMR Health Care
- CGEN Health Care
- Exchange
- LRMR Nasdaq
- CGEN Nasdaq
- Market Cap
- LRMR 204.9M
- CGEN 167.4M
- IPO Year
- LRMR N/A
- CGEN 2000
- Fundamental
- Price
- LRMR $3.88
- CGEN $1.53
- Analyst Decision
- LRMR Strong Buy
- CGEN
- Analyst Count
- LRMR 7
- CGEN 0
- Target Price
- LRMR $17.86
- CGEN N/A
- AVG Volume (30 Days)
- LRMR 892.3K
- CGEN 236.6K
- Earning Date
- LRMR 08-06-2025
- CGEN 08-06-2025
- Dividend Yield
- LRMR N/A
- CGEN N/A
- EPS Growth
- LRMR N/A
- CGEN N/A
- EPS
- LRMR N/A
- CGEN N/A
- Revenue
- LRMR N/A
- CGEN $27,589,000.00
- Revenue This Year
- LRMR N/A
- CGEN N/A
- Revenue Next Year
- LRMR N/A
- CGEN $105.77
- P/E Ratio
- LRMR N/A
- CGEN N/A
- Revenue Growth
- LRMR N/A
- CGEN N/A
- 52 Week Low
- LRMR $1.61
- CGEN $1.13
- 52 Week High
- LRMR $9.88
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- LRMR 69.65
- CGEN 41.35
- Support Level
- LRMR $3.11
- CGEN $1.49
- Resistance Level
- LRMR $4.01
- CGEN $1.64
- Average True Range (ATR)
- LRMR 0.27
- CGEN 0.08
- MACD
- LRMR 0.03
- CGEN -0.02
- Stochastic Oscillator
- LRMR 85.64
- CGEN 25.00
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.